GLP-1 receptor agonist use associated with improved patient-reported outcomes after lumbar spine surgery
Background
The rising prevalence of obesity and Type 2 diabetes mellitus (T2DM) significantly impacts outcomes after spine surgery, with both elevated BMI and poor glycemic control linked to poorer results. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for these conditions and have shown promise in improving perioperative outcomes like length of stay and infection rates in spine patients. However, data on their influence on crucial patient-reported outcome measures (PROMs), which capture functional recovery and quality of life, remain limited. This gap hinders comprehensive understanding of GLP-1 RA benefits in this surgical population.
Why It Matters
GLP-1 RA use before spine surgery could significantly improve patient recovery and quality of life, extending benefits beyond just reducing complications. This suggests clinicians might consider GLP-1 RAs as part of a comprehensive preoperative optimization strategy for patients with T2DM or obesity undergoing lumbar decompression or fusion. For individuals using GLP-1 RAs, this research reinforces their potential role in enhancing surgical outcomes, particularly in functional recovery. While specific dosing or timing protocols aren't detailed here, the general implication is that maintaining GLP-1 RA therapy pre-surgery could be beneficial. Further research is needed to establish definitive guidelines and explore optimal integration into surgical pathways.
glp-1-agonist
lumbar-spine-surgery
patient-reported-outcomes
t2dm
obesity
spinal-fusion